- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00613691
A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma
October 17, 2013 updated by: Spectrum Pharmaceuticals, Inc
This is a 2-part, open-label, single-arm, dose escalation study.
Part I will define the Maximum Tolerated Dose (MTD) and optimal dose of SPI-1620 and evaluate its PK and PD properties.
Once the MTD for SPI-1620 is identified, a second phase of the study will focus on dose escalation of docetaxel studied in groups of 3-6 patients.
This part of the study will assess the safety and tolerability of increasing doses of docetaxel administered with the optimal dose of SPI 1620 defined in Part I.
Study Overview
Detailed Description
This is a 2-part, open-label, single-arm, dose escalation study.
Part I will define the Maximum Tolerated Dose (MTD) and optimal dose of SPI-1620 and evaluate its PK and PD properties.
Eligible patients will receive SPI-1620 delivered intravenously over one minute on Days 1, 8 and 15.
On Day 8 patients will undergo a series of four H215O PET Blood Flow (BF) scans which will be used to assess alterations in BF induced by SPI-1620 in tumor and non-tumor ROIs (Region of Interest).
Fifteen minutes after receiving SPI-1620 on Day 15, patients will receive docetaxel, 60 mg/m2, administered by infusion over 1 hour.
Accelerated dose escalation of SPI-1620 will be employed: one patient will be treated at each dose level with 100% increases between dose levels.
If any grade 2 or higher, related AE occurs, the trial will revert to 3-patient cohorts with 40% dose escalation between groups.
There will be no intrapatient dose escalation.
Dose escalation will continue until there is either no further increase in tumor blood flow as assessed by H215O PET scan, or until significant toxicity is observed.
Once the MTD for SPI-1620 is identified, a second phase of the study will focus on dose escalation of docetaxel studied in groups of 3-6 patients.
This part of the study will assess the safety and tolerability of increasing doses of docetaxel administered with the optimal dose of SPI 1620 defined in Part I.
If 60 mg/m 2 was tolerated in Part I then up to six patients in Part II will receive docetaxel at a dose of 80 mg/m2 once every 3 weeks.
If this is tolerated the next group of patients will receive docetaxel 100 mg/m2 once every 3 weeks.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- START
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
All of the following inclusion criteria must be met prior to participation in this study
- The patient must sign an informed consent. A signed consent form is required prior to the performance of any protocol-related procedures or assessments.
- The patient must be >= 18 years of age.
- The patient must have progressive or recurrent carcinoma and has failed all standard therapies for his/her tumor.
- The patient must have a negative CT scan with contrast of the brain or MRI of the brain within 45 days of enrollment.
- The patient must be using an acceptable/effective method of contraception if she is a female patient of childbearing potential.
- The patient must have a negative serum pregnancy test within 14 days of entering the protocol if she is a female of childbearing potential.
- The patient must have an ECOG score <= 2.
- The patient must be willing and able to abide by the protocol.
Exclusion Criteria:
None of the exclusion criteria may be met prior to patient participation in this study
- The patient has a history of CHF, migraines, coagulopathy, stroke or inadequately controlled hypertension.
- The patient has asthma or symptomatic COPD.
- The patient has autonomic nerve dysregulation syndrome.
- The patient has angina or is taking nitrates or has had a MI within the past six months.
- The patient has a significant ventricular arrhythmia, class III or IV CHF or has a known coronary stenoses >80% and has not undergone either angioplasty or CABG
- The patient is taking phosphodiesterase inhibitors
- The patient has malignant or poorly controlled hypertension (>160/100)
- The patient has symptomatic orthostatic hypotension
- The patient is taking arterial vasodilators such as nifedipine or amlodipine or alpha blockers such as terazosin, tamsulosin and prazosin.
- The patient has a screening absolute neutrophil count less than 1.5 K/uL
- The patient has a screening platelet count less than 100 K/uL.
- The patient has a screening creatinine greater than 2.0 mg/dL
- The patient has a screening amino alanine transferase (ALT), or aspartate aminotransferase (AST) > 2.5 times the upper limit of the laboratory reference range or a total bilirubin > 1.0 mg/dL.
- The patient has a known immunodeficiency disorder.
- The patient is enrolled, or the patient plans to enroll, in any concurrent study of another investigational product.
- The patient is taking, or the patient is planning to take other cancer treatments during the study except for patients with prostate cancer using LHRH agonist therapy.
- The patient has a known hypersensitivity to any of the components of SPI 1620 or to docetaxel.
- The patient has previously failed treatment with docetaxel for his/her tumor and a dose of SPI-1620 that has been shown to enhance tumor blood flow has not been identified.
- The patient does not have a tumor that is at least 1cm. -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SPI-1620
SPI-1620 an endothelin B agonist
|
SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the safety and tolerability of SPI-1620 administered to patients with recurrent or progressive carcinoma who have failed all standard therapy.
Time Frame: every three weeks
|
every three weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the pharmacokinetic and pharmacodynamic profiles of SPI-1620 administered to patients with recurrent or progressive carcinoma who have failed all standard therapy.
Time Frame: one week
|
one week
|
To identify the optimum dose of SPI-1620 to be used in future Phase II studies.
Time Frame: every three weeks
|
every three weeks
|
To assess the safety and tolerability of doses of docetaxel from 60 mg/m2 to 100 mg/m2 when given following infusion of SPI 1620.
Time Frame: every three weeks
|
every three weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anthony Tolcher, MD, START
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
January 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
January 31, 2008
First Submitted That Met QC Criteria
February 12, 2008
First Posted (Estimate)
February 13, 2008
Study Record Updates
Last Update Posted (Estimate)
October 21, 2013
Last Update Submitted That Met QC Criteria
October 17, 2013
Last Verified
October 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPI-1620
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterEmbr Labs, Inc.Active, not recruitingHot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In SituUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
Institut BergoniéCompletedIntraductal Carcinoma and Lobular Carcinoma in SituFrance
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
Clinical Trials on SPI-1620
-
Spectrum Pharmaceuticals, IncTerminatedBiliary CancerUnited States
-
Spectrum Pharmaceuticals, IncTerminatedNon Small Cell Lung Cancer (NSCLC)United States
-
University of Firenze and Siena, Napoli, ItalyCompletedThick Gingival Margin to Tooth RestorationItaly
-
Pharmazz, Inc.RecruitingAcute Cerebral IschemiaIndia
-
Aisthesis Medical P.C.Larissa University Hospital; Technical University of CreteRecruitingInfections | Sepsis | Hemodynamic Instability | Abdominal Sepsis | Clinical DeteriorationGreece
-
Sparrow PharmaceuticalsRecruitingAutonomous Cortisol Secretion (ACS) | ACTH-Independent Cushing Syndrome | ACTH-Independent Adrenal Cushing Syndrome, SomaticUnited States, United Kingdom, France, Romania
-
Alpha - Bio Tec Ltd.CompletedImplant Clinical Survival | Dental Implant Bone LossChina
-
San Diego State UniversityNational Institute of Mental Health (NIMH)RecruitingSuicideUnited States
-
Pharmazz, Inc.Completed
-
Pharmazz, Inc.Not yet recruitingAcute Ischemic Stroke | Cerebral Stroke